ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2024; 14(2):879-891. doi:10.7150/thno.87843 This issue Cite
Research Paper
Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury
1. Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
2. Nanhu Brain-computer Interface Institute, Hangzhou, 311100, China.
3. Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
4. Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
5. Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China.
6. Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
7. National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
*These authors contributed equally to this work: Lijun Yang, Jian Cao.
Citation:
Yang L, Cao J, Du Y, Zhang X, Hong W, Peng B, Wu J, Weng Q, Wang J, Gao J. Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury. Theranostics 2024; 14(2):879-891. doi:10.7150/thno.87843. https://www.thno.org/v14p0879.htm
Other stylesAbstract
Rationale: Spinal cord injury (SCI) is an acute damage to the central nervous system that results in severe morbidity and permanent disability. Locally implanted scaffold systems with immobilized mesenchymal stem cells (MSCs) have been widely proven to promote locomotor function recovery in SCI rats; however, the underlying mechanism remains elusive.
Methods and Results: In this study, we constructed a hyaluronic acid scaffold system (HA-MSC) to accelerate the adhesive growth of human MSCs and prolong their survival time in SCI rat lesions. MSCs regulate local immune responses by upregulating the expression of anti-inflammatory cytokines. Interestingly, the dramatically increased, but transient expression of interleukin 10 (IL-10) is found to be secreted by MSCs in the first week. Blocking the function of the initially produced IL-10 by the antibody completely abolished the neurological and behavioral recovery of SCI rats, indicating a core role of IL-10 in SCI therapy with HA-MSC implantation. Transcriptome analyses indicated that IL-10 selectively promotes the migration and cytokine secretion-associated programs of MSCs, which in turn helps MSCs exert their anti-inflammatory therapeutic effects.
Conclusion: Our findings highlight a novel role of IL-10 in regulating MSC migration and cytokine secretion-associated programs, and determine the vital role of IL-10 in the domination of MSC treatment for spinal cord repair.
Keywords: mesenchymal stem cells, IL-10, spinal cord injury, cell migration, cytokines secretion
Citation styles
APA
Yang, L., Cao, J., Du, Y., Zhang, X., Hong, W., Peng, B., Wu, J., Weng, Q., Wang, J., Gao, J. (2024). Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury. Theranostics, 14(2), 879-891. https://doi.org/10.7150/thno.87843.
ACS
Yang, L.; Cao, J.; Du, Y.; Zhang, X.; Hong, W.; Peng, B.; Wu, J.; Weng, Q.; Wang, J.; Gao, J. Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury. Theranostics 2024, 14 (2), 879-891. DOI: 10.7150/thno.87843.
NLM
Yang L, Cao J, Du Y, Zhang X, Hong W, Peng B, Wu J, Weng Q, Wang J, Gao J. Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury. Theranostics 2024; 14(2):879-891. doi:10.7150/thno.87843. https://www.thno.org/v14p0879.htm
CSE
Yang L, Cao J, Du Y, Zhang X, Hong W, Peng B, Wu J, Weng Q, Wang J, Gao J. 2024. Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury. Theranostics. 14(2):879-891.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.